Neurology
Neonatal Seizure
7
Pipeline Programs↗
1
Active Trials↗
3
Companies Involved↗
Neonatal seizure is an early-stage landscape with 7 programs across 3 companies. The most active players are Mario Negri Institute for Pharmacological Research, Validus Pharmaceuticals, UCB.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical3
Phase 1
No programs
Phase 24
Phase 3
No programs
Approved
No programs
Analysis
Trial Status
14
clinical trials
Completed6 · 43%
Terminated5 · 36%
Withdrawn1 · 7%
Unknown status1 · 7%
Recruiting1 · 7%
Clinical Trials
Trial Activity
14 trials
Efficacy of Intravenous Levetiracetam in Neonatal Seizures
Completed·—·Phase 1/2·NCT01720667·280 enrolled
Pharmacokinetic and Safety Trial of Intravenous Levetiracetam in the Treatment of Neonatal Seizures
Completed·—·Phase 1/2·NCT00884052·18 enrolled
NEMO1:NEonatal Seizure Using Medication Off-patent
Completed·GGreat Ormond Street Hospital for Children NHS Foundation Trust·Phase 1/2·NCT01434225·14 enrolled
Efficacy of Keppra for Neonatal Seizures
Terminated·—·N/A·NCT01475656·2 enrolled
Levetiracetam Treatment of Neonatal Seizures
Terminated·—·Phase 1/2·NCT02550028·60 enrolled
Efficacy of Levetiracetam in Control of Neonatal Seizures Guided by an EEG
Unknown status·—·Phase 4·NCT03107507·40 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)